tiprankstipranks
Argenx and Zai Lab’s CIDP Drug Approved in China
Company Announcements

Argenx and Zai Lab’s CIDP Drug Approved in China

Argenx Se (ARGX) has released an update.

Don't Miss our Black Friday Offers:

Argenx SE and Zai Lab Limited have announced that their drug VYVGART Hytrulo has received approval from China’s National Medical Products Administration for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), marking it as the first approved therapy for this condition in China. This approval is seen as a significant advancement for patients who have long been in need of effective treatment options. The decision is based on successful trial results showing a substantial reduction in CIDP relapse risk.

For further insights into ARGX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyArgenx price target raised to EUR 670 from EUR 650 at Barclays
TheFlyArgenx price target raised to $706 from $675 at Evercore ISI
TheFlyArgenx price target raised to $675 from $646 at Oppenheimer
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App